The new Scandinavian Life Science Funding Report from Industrifonden shows that Scandinavian life science companies raised $2.2 billion in 2017, doubling the amount raised in 2016. Sweden maintains its position as the main market for funding of innovative life science companies.
“It is extremely pleasing and confirms our view that interest from national and international investors has never been greater. The emerging segment of digital health, and its intersections with healthcare, pharma, medtech and ICT, is especially interesting to venture capitalists”, says Carl-Peter Mattson, Business Advisor, responsible for investor relations and capital issues at Sahlgrenska Science Park.
Read more in the interesting report in Nordic Life Science.
Text: Annika Åkervall